FDA approves a second Alzheimer's drug that can modestly slow disease
What is the main benefit of Eli Lilly’s Kisunla?
Eli Lilly's Kisunla is an Alzheimer's drug that can modestly slow the disease, providing a new option for patients in the early stages of the incurable, memory-destroying ailment3. It is the second drug that has been convincingly shown to delay cognitive decline in patients. The delay seen with Kisunla amounts to about seven months.
How does Kisunla's administration frequency compare to Leqembi's?
Kisunla is administered once a month, while Leqembi is administered twice a month. This makes Kisunla's administration frequency half that of Leqembi's, potentially making it a more convenient option for caregivers and patients.
What are the main side effects of Kisunla?
The main side effects of Kisunla include brain swelling, bleeding, headache, and swelling in areas of the brain with or without small spots of bleeding2. These side effects occurred in at least 10% of patients and at a higher incidence compared to placebo2. Serious allergic reactions and infusion-related reactions may also occur.